To amend title XVIII of the Social Security Act to ensure equitable payment for, and preserve Medicare beneficiary access to, cancer treatments under the Medicare hospital outpatient prospective payment system.
Summary
HR8032 (FAIC Act) mandates separate Medicare Part B payment for qualifying cancer drugs, preventing hospitals from absorbing high-cost oncology products into bundled outpatient payments. This eliminates a structural disincentive against administering expensive branded cancer therapies, directly protecting $50B+ in oncology drug revenue at companies like Merck, J&J, Bristol-Myers, Pfizer, Lilly, and Amgen. The stock prices of these tickers currently trade at depressed levels relative to their 52-week ranges (most down 2-8% over 30 days), presenting a potential catalyst when the bill advances.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR8032 mandates separate Medicare Part B payment for cancer drugs with per-day cost ≥ $350, preventing hospitals from absorbing high-cost cancer drugs into bundled payments.
- 2.Merck ($MRK) and Johnson & Johnson ($JNJ) are the most exposed, with Keytruda (~$25B revenue) and Darzalex (~$12B) as the largest infused oncology products protected by the bill.
- 3.All six affected tickers trade below their 30-day moving averages, suggesting the market has not priced in this legislative catalyst — asymmetry is favorable for long holders.
- 4.The FAIC Act is early-stage (referred to committee) with 8 months remaining in the 119th Congress; bipartisan sponsorship and narrow scope improve passage probability.
Market Implications
The market is currently pricing zero probability of HR8032 passage into oncology stock valuations. MRK at $110.03 is 12% off its 52-week high ($125.14); BMY at $58.26 is 7% off its high ($62.89); PFE at $26.48 is 8% off ($28.75). All show negative 7-day and 30-day momentum, indicating sector-wide selling pressure unrelated to this legislation. If the bill advances (committee markup or CBO score), expect a catalyst-driven re-rating of 3-8% for MRK, JNJ, and BMY specifically, as their oncology revenue exposure is highest as a percentage of market cap. The $350 threshold captures virtually all infused cancer therapies — Keytruda, Opdivo, Darzalex, and Imbruvica all easily exceed this per-day cost. The legislative path is the key variable: passage would be bullish; failure to advance leaves the structural disincentive in place.
Full Analysis
Market Impact Score
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Protecting Americans from Unsafe Drugs Act of 2026
To amend title XVIII of the Social Security Act to require PDP sponsors of a prescription drug plan under part D of the Medicare program that use a formulary to include certain generic drugs and biosimilar biological products on such formulary, and for other purposes.
Most Favored Patient Act of 2026
GAP Supply Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.